Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Memphis Meats Produces World’s First Poultry from Animal Cells

XTALKS VITALS NEWS

Chicken

Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Share this!

March 17, 2017 | by Sarah Hand, M.Sc.

What if consumers could enjoy eating meat, without contributing to the negative environmental effects of conventional livestock farming practices? Now, Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Chicken is an incredibly popular source of protein in the US, representing a $90 billion dollar a year industry. American consumers eat approximately 90 pounds of chicken per year.

While duck may not be as common in the US, it is more prevalent in other areas around the world, including mainland China. Consumers in the country eat over 6 billion pounds of duck per year.

“It is thrilling to introduce the first chicken and duck that didn’t require raising animals,” said Dr. Uma Valeti, co-founder and CEO of Memphis Meats. “This is a historic moment for the clean meat movement.”

Using their own technological platform, their poultry was grown from cultured chicken and duck stem cells. According to Memphis Meats, their method will allow for the production of multiple different types of meat, with the ability to control taste, texture and nutritional content.



“Chicken and duck are at the center of the table in so many cultures around the world, but the way conventional poultry is raised creates huge problems for the environment, animal welfare, and human health,” continued Valeti. “It is also inefficient.”

As with most new technologies, the company’s operation is currently on the small side and the meat is expensive to grow. Still, Memphis Meats anticipates being able to scale-up the technology, while reducing costs, to meet their goal of launching their consumer meat products in 2021.

“We aim to produce meat in a better way, so that it is delicious, affordable and sustainable. We really believe this is a significant technological leap for humanity, and an incredible business opportunity—to transform a giant global industry while contributing to solving some of the most urgent sustainability issues of our time.”

In early 2016, Memphis Meats became the first to produce a meatball composed entirely of lab-grown beef. The global meat market is a $750 billion industry, which Memphis Meats hopes to tap into with its slaughter-free meats.


Keywords: Food, Meat, Cell Culture


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.